USC NORRIS CANCER HOSPITAL
1. Target Overview & Investment Thesis
USC NORRIS CANCER HOSPITAL is a 60-bed suburban community hospital in LOS ANGELES, CA with $468.7M in net patient revenue and a 19.1% operating margin. The hospital serves a payer mix of 24.3% Medicare, 15.7% Medicaid, and 60.0% commercial.
Thesis: Turnaround. Our ML models identify $34.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 19.1% to 26.5% (+736bps).
| Net Revenue HCRIS | $468.7M |
| Current EBITDA COMPUTED | $89.5M |
| Operating Margin COMPUTED | 19.1% |
| Occupancy HCRIS | 60.2% |
| Revenue / Bed COMPUTED | $7.8M |
| Net-to-Gross HCRIS | 28.6% |
| Distress Probability ML | 38.7% |
2. Market Context & Competitive Position
CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of 19.1% places it above the state median. Among 124 size-comparable peers (30-120 beds), the median margin is -6.6%. The target performs in line with or above peers.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (30-120), prioritizing same-state peers. 124 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| USC NORRIS CANCER HOSPITAL (Target) | CA | 60 | $468.7M | 19.1% |
| RANCHO LOS AMIGOS NATL.REHAB.C | CA | 83 | $512.6M | 41.9% |
| KFH - FREMONT | CA | 100 | $296.2M | -6.6% |
| QUEEN OF THE VALLEY MEDICAL CE | CA | 119 | $293.8M | -16.7% |
| MERCY HOSPITAL OF FOLSOM | CA | 106 | $287.8M | 17.0% |
| MARSHALL HOSPITAL | CA | 111 | $286.0M | -5.9% |
| KFH - SOUTH SAN FRANCISCO | CA | 120 | $284.6M | -0.0% |
| LLUMC MURRIETA | CA | 111 | $276.7M | -20.3% |
| ADVENTIST HEALTH SONORA | CA | 84 | $274.3M | -7.4% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $34.5M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $9.8M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $9.4M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $9.3M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $5.7M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $300K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $89.5M |
| + RCM Uplift | +$34.5M |
| Pro Forma EBITDA | $124.0M |
| Current Margin | 19.1% |
| Pro Forma Margin | 26.5% |
| WC Released (1x) | $18.0M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $137.7M | $935.2M | 6.79x | 46.7% |
| Base (11x exit) | 10.0x | 11.0x | $137.7M | $1.07B | 7.80x | 50.8% |
| Bull Case | 9.0x | 11.0x | $123.9M | $1.23B | 9.94x | 58.3% |
| Bull (12x exit) | 9.0x | 12.0x | $123.9M | $1.38B | 11.14x | 62.0% |
| Bear Case | 11.0x | 10.0x | $151.4M | $718.0M | 4.74x | 36.5% |
| Bear (11x exit) | 11.0x | 11.0x | $151.4M | $839.0M | 5.54x | 40.8% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| Medium | Standard execution risk | RCM improvement requires management buy-in and 12-18 month implementation timeline |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 124 hospitals with 30-120 beds
- Same-state prioritization (n=125)
- Comp margins: P25=-23.8% / P50=-6.6% / P75=1.7%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.